Ovarian suppression for prevention of premature menopause and infertility: Empty promise or effective therapy?

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 479-481

  Partridge, Ann H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; INHIBIN; TAMOXIFEN; TRIPTORELIN;

AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CRYOPRESERVATION; EARLY MENOPAUSE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; MENSTRUAL CYCLE; NONHUMAN; NOTE; OVARIAN SUPPRESSION; OVARY FUNCTION; OVULATION; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION;

AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FERTILITY; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; NEOADJUVANT THERAPY; OVARY; TRIPTORELIN PAMOATE;

EID: 84856939864     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.9883     Document Type: Note

References (14)

1. Partridge AH, Ruddy KJ: Fertility and adjuvant treatment in young women with breast cancer. Breast 16:S175-S181, 2007 (suppl 2)
2. Swain SM, Jeong JH, Geyer CE Jr, et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-2065, 2010
3. Swain SM, Jeong JH, Wolmark N: Amenorrhea from breast cancer therapy: Not a matter of dose. N Engl J Med 363:2268-2270, 2010
4. Pagani O, O'Neill A, Castiglione M, et al: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998
5. Parulekar WR, Day AG, Ottaway JA, et al: Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study - NCIC CTG MA.5. J Clin Oncol 23:6002-6008, 2005
6. Partridge AH, Ruddy KJ, Gelber S, et al: Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94:638-644, 2010
7. Walshe JM, Denduluri N, Swain SM: Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769-5779, 2006 (Pubitemid 46646480)
8. Sonmezer M, Oktay K: Fertility preservation in young women undergoing breast cancer therapy. Oncologist 11:422-434, 2006 (Pubitemid 43788268)
9. Munster PN, Moore AP, Ismail-Khan R, et al: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533-538, 2012
10. Gerber B, von Minckwitz G, Stehle H, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
11. Leonard RC, Adamson D, Anderson R, et al: The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 28:89s, 2010 (suppl 15; abstr 590)
12. Del Mastro L, Boni L, Michelotti A, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA 306:269-276, 2011
13. Badawy A, Elnashar A, El-Ashry M, et al: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril 91:694-697, 2009
14. Southwest Oncology Group Protocol Fast Fact Sheet: SWOG S0230: Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard in Early Stage, Hormone-Receptor Negative Breast Cancer. http://swog.org/intergroup/GetSecuredFile.asp?ProtocolNumber=S0230& AccessCode=p5guFuf&Document~MISC1-0230.pdf